Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients

We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and...

Full description

Saved in:
Bibliographic Details
Published in:Critical reviews in oncology/hematology 2023-10, Vol.190, p.104113, Article 104113
Main Authors: Jiang, Yaofei, Fang, Ting, Lu, Nian, Bei, Weixin, Dong, Shuhui, Xia, Weixiong, Liang, Hu, Xiang, Yanqun
Format: Article
Language:English
Subjects:
Anti-angiogenesis
EGFR inhibitors
Nasopharyngeal carcinoma
PD1 inhibitors
Prognosis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793
cites cdi_FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793
container_end_page
container_issue
container_start_page 104113
container_title Critical reviews in oncology/hematology
container_volume 190
creator Jiang, Yaofei
Fang, Ting
Lu, Nian
Bei, Weixin
Dong, Shuhui
Xia, Weixiong
Liang, Hu
Xiang, Yanqun
description We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p 
doi_str_mv 10.1016/j.critrevonc.2023.104113
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2857853320</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842823002019</els_id><sourcerecordid>2857853320</sourcerecordid><originalsourceid>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</originalsourceid><addsrcrecordid>eNqFkctOwzAQRSMEElD4By_ZpPiV1xJKeUiVQMDecpxp6yqxi-0W8TN8K1MFiSUrWzN3juf6ZhlhdMooK683UxNsCrD3zkw55QLLkjFxlJ2xumpyKkt2jHcqaV5LXp9m5zFuKKVSltVZ9n3jks1f7hgJYNa678GtgFhHjB9a63Sy3pFPm9ZEH4TaraxfgYNoI_FhLM4f7l8JrqDTAC6RFr6868g2-FWAGA8A5CF-FwL2rwdIOiYkG-J09Nu1Dl_4qO6J0cFY5wdNtthGbbzITpa6j3D5e06yt_v5--wxXzw_PM1uFrmRlKWcN00DALyiXHKhBW-XphGikBLKspOsKyvWFiUVbdFwUTDBdFMbxoq6ElUjJtnVSMWdP3YQkxpsNND32oHfRcXroqoLIThFaT1KTfAxBliqbbADOlCMqkMgaqP-AlGHQNQYCI7ejqOARvYWgooGTRroLH5OUp23_0N-AOYInGY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2857853320</pqid></control><display><type>article</type><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><source>Elsevier</source><creator>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</creator><creatorcontrib>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</creatorcontrib><description>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p &lt; 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents. [Display omitted] •R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</description><identifier>ISSN: 1040-8428</identifier><identifier>ISSN: 1879-0461</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2023.104113</identifier><language>eng</language><publisher>Elsevier B.V</publisher><subject>Anti-angiogenesis ; EGFR inhibitors ; Nasopharyngeal carcinoma ; PD1 inhibitors ; Prognosis</subject><ispartof>Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104113, Article 104113</ispartof><rights>2023 The Authors</rights><rights>Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</citedby><cites>FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Fang, Ting</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><creatorcontrib>Liang, Hu</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><title>Critical reviews in oncology/hematology</title><description>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p &lt; 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents. [Display omitted] •R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</description><subject>Anti-angiogenesis</subject><subject>EGFR inhibitors</subject><subject>Nasopharyngeal carcinoma</subject><subject>PD1 inhibitors</subject><subject>Prognosis</subject><issn>1040-8428</issn><issn>1879-0461</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkctOwzAQRSMEElD4By_ZpPiV1xJKeUiVQMDecpxp6yqxi-0W8TN8K1MFiSUrWzN3juf6ZhlhdMooK683UxNsCrD3zkw55QLLkjFxlJ2xumpyKkt2jHcqaV5LXp9m5zFuKKVSltVZ9n3jks1f7hgJYNa678GtgFhHjB9a63Sy3pFPm9ZEH4TaraxfgYNoI_FhLM4f7l8JrqDTAC6RFr6868g2-FWAGA8A5CF-FwL2rwdIOiYkG-J09Nu1Dl_4qO6J0cFY5wdNtthGbbzITpa6j3D5e06yt_v5--wxXzw_PM1uFrmRlKWcN00DALyiXHKhBW-XphGikBLKspOsKyvWFiUVbdFwUTDBdFMbxoq6ElUjJtnVSMWdP3YQkxpsNND32oHfRcXroqoLIThFaT1KTfAxBliqbbADOlCMqkMgaqP-AlGHQNQYCI7ejqOARvYWgooGTRroLH5OUp23_0N-AOYInGY</recordid><startdate>202310</startdate><enddate>202310</enddate><creator>Jiang, Yaofei</creator><creator>Fang, Ting</creator><creator>Lu, Nian</creator><creator>Bei, Weixin</creator><creator>Dong, Shuhui</creator><creator>Xia, Weixiong</creator><creator>Liang, Hu</creator><creator>Xiang, Yanqun</creator><general>Elsevier B.V</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202310</creationdate><title>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</title><author>Jiang, Yaofei ; Fang, Ting ; Lu, Nian ; Bei, Weixin ; Dong, Shuhui ; Xia, Weixiong ; Liang, Hu ; Xiang, Yanqun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Anti-angiogenesis</topic><topic>EGFR inhibitors</topic><topic>Nasopharyngeal carcinoma</topic><topic>PD1 inhibitors</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jiang, Yaofei</creatorcontrib><creatorcontrib>Fang, Ting</creatorcontrib><creatorcontrib>Lu, Nian</creatorcontrib><creatorcontrib>Bei, Weixin</creatorcontrib><creatorcontrib>Dong, Shuhui</creatorcontrib><creatorcontrib>Xia, Weixiong</creatorcontrib><creatorcontrib>Liang, Hu</creatorcontrib><creatorcontrib>Xiang, Yanqun</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jiang, Yaofei</au><au>Fang, Ting</au><au>Lu, Nian</au><au>Bei, Weixin</au><au>Dong, Shuhui</au><au>Xia, Weixiong</au><au>Liang, Hu</au><au>Xiang, Yanqun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><date>2023-10</date><risdate>2023</risdate><volume>190</volume><spage>104113</spage><pages>104113-</pages><artnum>104113</artnum><issn>1040-8428</issn><issn>1879-0461</issn><eissn>1879-0461</eissn><abstract>We aim to evaluate the efficacy and safety of anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC) patients who progressed to previous anti-PD1 therapy. Enrolled patients were divided into a combination group and a chemotherapy only group. A total of 145 patients were enrolled. The median progress-free survival (mPFS) was 7.9 months and 4.4 months, respectively for the two groups. The combination group exhibited significantly longer PFS (HR=0.363, p &lt; 0.001), and better disease control ratio (DCR, p = 0.022) compared with the chemotherapy group. Among the combination group, longer PFS was found in those patients who received different PD1 inhibitor from prior therapy, reached object response rate (ORR) from prior anti-PD1 therapy, and EBV DNA ≤ 1500 copy/ml before therapy, comparing to the corresponding other patients. R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR agents. [Display omitted] •R/M NPC patients who progressed from prior anti-PD1 therapy could benefit from the anti-PD1 rechallenge combination therapy.•Adverse reactions of the combination therapy were tolerable.•Those who reached ORR from prior anti-PD1 therapy, EBV DNA ≤ 1500 copy/ml, and got different PD1 inhibitor, benefit more.</abstract><pub>Elsevier B.V</pub><doi>10.1016/j.critrevonc.2023.104113</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1040-8428
ispartof Critical reviews in oncology/hematology, 2023-10, Vol.190, p.104113, Article 104113
issn 1040-8428
1879-0461
1879-0461
language eng
recordid cdi_proquest_miscellaneous_2857853320
source Elsevier
subjects Anti-angiogenesis
EGFR inhibitors
Nasopharyngeal carcinoma
PD1 inhibitors
Prognosis
title Anti-PD1 rechallenge in combination with anti-angiogenesis or anti-EGFR treatment beyond progression in recurrent/metastatic nasopharyngeal carcinoma patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T12%3A48%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Anti-PD1%20rechallenge%20in%20combination%20with%20anti-angiogenesis%20or%20anti-EGFR%20treatment%20beyond%20progression%20in%20recurrent/metastatic%20nasopharyngeal%20carcinoma%20patients&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Jiang,%20Yaofei&rft.date=2023-10&rft.volume=190&rft.spage=104113&rft.pages=104113-&rft.artnum=104113&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2023.104113&rft_dat=%3Cproquest_cross%3E2857853320%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c401t-2999eee2702423a32bfc933544e66d41d671b5603b59235131a98c115873793%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2857853320&rft_id=info:pmid/&rfr_iscdi=true